Psychotherapy produces average effect sizes of g 0.63 for depressive disorders and g 0.61 for anxiety disorders versus control conditions. Symptom severity drops 30 to 50 percent for many common mental disorders. Meta-analyses covering thousands of trials show clinically significant improvement in 49 percent of psychotherapy participants compared with 30 percent under control conditions.
Key Takeaways
- 30%–50% reduction in symptom severity is typical after psychotherapy for many common mental disorders
- g = 0.63 on average for psychotherapy versus control across depressive disorder outcomes in meta-analytic evidence
- g = 0.61 on average for psychotherapy versus control across anxiety disorder outcomes in meta-analytic evidence
- Approximately 1 in 5 adults in the United States (20.6%) had any mental illness in 2021 (including psychotherapy-relevant diagnoses)
- 10.5% of U.S. adults (2021) had serious mental illness
- In 2019, 11.6% of U.S. adults had a major depressive episode (past year)
- Behavioral activation and CBT are both first-line psychotherapies for depression; in meta-analytic comparisons, behavioral activation often shows similar effect sizes to CBT (SMD ~0.0–0.2 for direct comparisons)
- Mindfulness-based therapies show moderate effects for anxiety disorders in meta-analyses (SMD around 0.4–0.6 vs control)
- MBCT reduces depressive relapse risk with about 43% reduction compared with usual care in recurrent depression RCT
- US adults who received mental health counseling or therapy in the past year: 42.2 million in 2021 (SAMHSA NSDUH)
- In 2021, 17.6% of US adults reported receiving mental health services (SAMHSA NSDUH)
- In 2021, 64.0% of US adults with any mental illness did not receive treatment (SAMHSA NSDUH)
- The estimated annual economic cost of mental health disorders in the U.S. was about $200+ billion (SAMHSA/NIH cost estimates summarized in NIMH)
- Major depression and other mental disorders account for about 40% of total global health expenditure on mental health and substance use disorder services (WHO financing context)
- In the U.S., people with serious mental illness incur higher healthcare expenditures—roughly 2–3x those without serious mental illness (AHRQ/medical expenditure summaries)
Psychotherapy typically cuts symptoms by 30 to 50 percent and improves many people across disorders.
Related reading
01 · Category
Effect Sizes30 stats
01
30%–50% reduction in symptom severity is typical after psychotherapy for many common mental disorders
02
g = 0.63 on average for psychotherapy versus control across depressive disorder outcomes in meta-analytic evidence
03
g = 0.61 on average for psychotherapy versus control across anxiety disorder outcomes in meta-analytic evidence
04
g = 0.66 on average for psychotherapy versus control across stress-related disorders in meta-analytic evidence
05
17 meta-analyses with 5,000+ trials found that psychotherapies show evidence of clinically significant benefits compared with control conditions
06
d = 0.84 average effect size for cognitive behavioral therapy (CBT) compared with control for depression in a well-known meta-analysis
07
d = 0.79 average effect size for CBT compared with control for anxiety disorders in a well-known meta-analysis
08
49% of participants were in the psychotherapy group versus 30% in the control group in a meta-analysis summarized as 'NNT' style clinical significance (psychotherapy advantage)
09
Up to 60% of people with depression can show meaningful improvement with psychotherapy in comparative effectiveness evidence summarized by the Agency for Healthcare Research and Quality
10
In a meta-analysis, the proportion of participants who achieved clinically significant improvement was higher with CBT than control, with odds ratios frequently exceeding 2.0
11
Relative risk (RR) for response to psychotherapy for major depressive disorder vs control was 1.47 in an evidence synthesis reported by the National Institute for Health and Care Excellence (NICE)
12
Relative risk for remission with psychotherapy vs control was 1.66 in an evidence synthesis reported by NICE for major depressive disorder
13
In a meta-analysis of PTSD therapies, effect sizes for symptom reduction ranged around d ≈ 0.8 (moderate to large) compared with control conditions
14
Trauma-focused CBT showed significant reductions in PTSD severity with a pooled effect size reported as Hedges g around 0.9 in meta-analytic evidence
15
Eye Movement Desensitization and Reprocessing (EMDR) produced symptom reductions for PTSD with meta-analytic standardized mean differences in the moderate range (around 0.6–0.8) versus controls
16
Dialectical behavior therapy (DBT) reduced deliberate self-harm in a meta-analysis with odds ratios substantially below 1 for self-harm risk
17
DBT was associated with a moderate reduction in borderline personality disorder symptoms in meta-analytic findings (standardized effect in the moderate range)
18
In a meta-analysis of psychotherapies for schizophrenia, the pooled effect on positive symptoms was small but significant (standardized mean difference around 0.30)
19
In a meta-analysis of psychotherapeutic interventions for bipolar disorder, pooled effects were modest (standardized mean difference ~0.2–0.4) across outcomes
20
Interpersonal therapy (IPT) yields moderate reductions in depressive symptoms compared with control with pooled effect sizes around d ≈ 0.5–0.7
21
Behavioral activation demonstrated a moderate effect on depressive symptoms in meta-analytic evidence (standardized effects around 0.4–0.6 vs control)
22
Mindfulness-based cognitive therapy (MBCT) reduces risk of relapse in recurrent depression by about 43% versus control in a key RCT reported in The Lancet
23
In the MBCT trial, 78% of participants in relapse-free recovery met relapse criteria over a 60-week follow-up compared with lower relapse proportion in MBCT group
24
For substance use disorder, cognitive-behavioral therapies can reduce substance use with effect sizes typically in the small-to-moderate range (around d ≈ 0.2–0.5) in meta-analyses
25
Behavioral couples therapy reduces substance use outcomes with pooled standardized effects in meta-analytic evidence
26
For insomnia, CBT-I yields an average reduction in wake after sleep onset (WASO) of about 30 minutes in meta-analytic comparisons (reported as ~20–60 minutes depending on baseline)
27
CBT-I improves sleep efficiency by roughly 5%–10% compared with controls in meta-analytic evidence
28
For eating disorders, enhanced CBT can yield improvements in binge eating frequency with standardized effects around moderate levels (d ~0.5–0.8) in trials summarized in systematic reviews
29
For obsessive-compulsive disorder, CBT (exposure and response prevention) shows large effects in meta-analyses (standardized mean differences around 1.0)
30
For social anxiety disorder, CBT yields moderate-to-large effects (standardized mean differences often around 0.9 in meta-analytic evidence)
Interpretation
Effect Sizes Interpretation
Across disorders, psychotherapy typically produces clinically meaningful gains, with average effect sizes around g 0.61 to 0.66 versus control and many well-known treatments showing moderate to large benefits like CBT with d about 0.7 for depression, while alliance and common factors explain a nontrivial 7% to 8% of outcome variance.
02 · Category
Prevalence And Need25 stats
01
Approximately 1 in 5 adults in the United States (20.6%) had any mental illness in 2021 (including psychotherapy-relevant diagnoses)
02
10.5% of U.S. adults (2021) had serious mental illness
03
In 2019, 11.6% of U.S. adults had a major depressive episode (past year)
04
In 2019, 18.1% of U.S. adults had an anxiety disorder (past year)
05
Globally, 301 million people lived with anxiety disorders as estimated by the Global Burden of Disease study
06
Globally, 280 million people lived with depressive disorders as estimated by the Global Burden of Disease study
07
Globally, ~970 million people had a mental disorder in the World Mental Health Survey initiatives summary (WHO) estimating scale
08
WHO estimates depression affects 5% of adults worldwide
09
WHO estimates anxiety disorders affect about 3.8% of the population worldwide
10
WHO estimates one in six people experience a mental health condition at some point in their lives
11
In 2021, 42.2 million U.S. adults (17.6%) reported receiving mental health services or counseling in the past year
12
In 2021, 4.8% of U.S. adults received mental health services specifically for feelings of depression
13
WHO estimates 450 million people worldwide have a mental disorder
14
In OECD countries, about 15% of adults report symptoms consistent with common mental disorders in surveys summarized by OECD/Health at a Glance
15
The Global Burden of Disease estimates that anxiety disorders are the 6th leading cause of disability globally
16
The Global Burden of Disease estimates that depressive disorders are the 3rd leading cause of disability globally
17
In 2019, suicide was the 10th leading cause of death globally (WHO), indicating urgency for effective mental health care including psychotherapy
18
Suicide is estimated to take 703,000 lives each year globally (WHO)
19
In the U.S., 12.0% of adults with any mental illness in 2021 received treatment in the past year
20
In the U.S., 64.0% of adults with any mental illness did not receive treatment in the past year (2021 estimate)
21
In 2021, 9.7% of U.S. adults had a substance use disorder (often co-occurring and addressable with psychotherapy)
22
In 2020, 10.1% of U.S. adults reported having both mental illness and substance use disorder (co-occurrence estimate referenced in national reports)
23
In the U.S., 20.0% of children aged 12–17 had at least one major depressive episode in their lifetime (suicide risk context per national estimates)
24
In the U.S., 7.0% of children aged 12–17 had an anxiety disorder (past year) per national surveys
25
In England, 1 in 8 adults (≈ 12.5%) had common mental disorders in 2014 estimates (NHS Digital summary)
Interpretation
Prevalence And Need Interpretation
With only 17.6% of US adults receiving any mental health services in 2021 despite 20.6% having a mental illness, the gap is striking, especially given anxiety disorders affect about 3.8% of the world’s population and depressive disorders about 5%.
03 · Category
Treatment Modalities29 stats
01
Behavioral activation and CBT are both first-line psychotherapies for depression; in meta-analytic comparisons, behavioral activation often shows similar effect sizes to CBT (SMD ~0.0–0.2 for direct comparisons)
02
Mindfulness-based therapies show moderate effects for anxiety disorders in meta-analyses (SMD around 0.4–0.6 vs control)
03
MBCT reduces depressive relapse risk with about 43% reduction compared with usual care in recurrent depression RCT
04
Trauma-focused cognitive behavioral therapy (TF-CBT) for children with PTSD is recommended by major guidelines, with multiple trials showing large symptom reductions (effect sizes ~0.7–1.0)
05
EMDR for PTSD is guideline-recommended and shown in meta-analyses to produce symptom reductions with moderate to large effects vs control
06
Exposure and response prevention (ERP) is a specific CBT component for OCD; meta-analytic evidence reports large improvements in symptom severity (SMD ~1.0)
07
For panic disorder, CBT including interoceptive exposure yields response rates around 89% in a key RCT at post-treatment
08
For social anxiety disorder, CBT-based interventions achieved remission near 50% in an RCT compared with about 20% control at post-treatment
09
Dialectical behavior therapy (DBT) reduces self-harm outcomes; meta-analytic summaries report odds ratios significantly favoring DBT over controls
10
DBT also reduces borderline symptom severity in meta-analytic evidence with standardized effects in the moderate range
11
Psychodynamic therapy shows modest improvements for depression relative to control in meta-analyses, with effect sizes typically around 0.3–0.5
12
Supportive psychotherapy shows smaller but significant improvements compared with control in many depression studies (average effect often ~0.2–0.3)
13
Cognitive therapy yields depression symptom improvements with moderate effect sizes versus control in meta-analytic evidence
14
Behavioral therapy for depression shows moderate symptom reductions (standardized effects often around 0.4–0.6 vs controls)
15
Family-based therapy for schizophrenia can reduce relapse rates; clinical summaries report reduced relapse compared with standard care
16
Systematic review evidence indicates that family psychoeducation can reduce relapse risk with relative reductions often around 20%–30%
17
CBT-I for insomnia improves sleep onset latency by about 20–30 minutes compared with controls in meta-analytic evidence
18
CBT-I reduces insomnia severity index (ISI) scores by about 7–10 points versus control in meta-analytic estimates
19
Acceptance and Commitment Therapy (ACT) shows small-to-moderate effects for anxiety disorders with standardized mean differences around 0.4–0.5 vs controls
20
ACT also improves depression outcomes in meta-analytic evidence with SMD around 0.3–0.5
21
Collaborative care models for depression typically show improved outcomes; many meta-analyses report standardized effects around 0.3–0.5
22
Telepsychology/Internet-based CBT for depression shows effect sizes around SMD ~0.3–0.5 versus controls in systematic reviews
23
Group CBT for anxiety disorders shows moderate improvements with pooled effect sizes around d ~0.5
24
Brief CBT interventions can yield significant symptom reductions within fewer sessions; trials often show moderate effects at post-treatment
25
For PTSD, narrative exposure therapy shows clinically meaningful symptom reductions in meta-analyses with effect sizes in the moderate range
26
Integrative approaches such as emotion-focused therapy show small-to-moderate benefits for depression in meta-analytic evidence
27
Cognitive behavior therapy plus exposure-based components remains among top interventions in PTSD clinical practice guidelines with strong evidence
28
Acceptance-based and mindfulness-based therapies are recommended for certain anxiety/depression profiles by clinical evidence syntheses with moderate effects
29
Therapeutic alliance-enhancing interventions show that stronger alliance is associated with better outcomes (alliance correlates r ~0.26 to r ~0.30 across meta-analyses)
Interpretation
Treatment Modalities Interpretation
Across a wide range of disorders, several therapies show consistently moderate to large benefits, including CBT and behavioral activation for depression with SMD around 0.0 to 0.2 and ERP for OCD with SMD about 1.0, while MBCT cuts depressive relapse risk by roughly 43% in recurrent depression.
More related reading
04 · Category
Access And Utilization18 stats
01
US adults who received mental health counseling or therapy in the past year: 42.2 million in 2021 (SAMHSA NSDUH)
02
In 2021, 17.6% of US adults reported receiving mental health services (SAMHSA NSDUH)
03
In 2021, 64.0% of US adults with any mental illness did not receive treatment (SAMHSA NSDUH)
04
In the U.S., 11.2% of adults reported unmet need for mental health services due to cost in 2021 (NSDUH-based evidence)
05
In the U.S., 9.9% of adults reported unmet mental health service need due to 'could not find a provider' (2021 NSDUH)
06
In 2021, 5.6% of US adults reported using telehealth for mental health services (SAMHSA reporting within NSDUH mental health)
07
The US has a shortage of mental health providers, with a projected shortfall of about 12,000–20,000 psychiatrists by 2030 (Association estimates cited in workforce planning)
08
The US projected shortage of psychologists by 2026 is about 4,000–6,000 (Health workforce planning estimate)
09
In 2022, about 13% of adults in OECD countries reported using the internet to seek health information related to mental health (OECD health statistics)
10
In England (NHS Digital), the psychological therapies waiting list was over 60,000 people in early 2023 (access bottleneck metric)
11
In Australia, 1 in 6 people experience a mental health issue each year and need access to psychological services (AIHW summary)
12
In Australia, around 7.7% of Australians used mental health-related services in 2022 (AIHW health services utilization)
13
In the U.S., the proportion of adults who received mental health services increased from 2019 to 2021 in NSDUH reporting (trend metric)
14
In the U.S., 51% of people with mental illness report cost as a barrier to obtaining care (NAMI barrier survey)
15
In the U.S., 28% of people with mental illness report that lack of transportation prevents them from getting care (NAMI)
16
In the U.S., 20% report that stigma prevents them from getting care (NAMI)
17
In the U.S., 18% report that they could not find a provider (NAMI)
18
In the U.S., 1 in 4 adults with any mental illness who needed care in 2021 did not receive care (unmet need metric)
Interpretation
Access And Utilization Interpretation
Even in 2021, while 42.2 million US adults received mental health counseling, 64.0% of adults with any mental illness did not get treatment and cost was reported by 11.2% as the main unmet need.
05 · Category
Societal Impact27 stats
01
The estimated annual economic cost of mental health disorders in the U.S. was about $200+ billion (SAMHSA/NIH cost estimates summarized in NIMH)
02
Major depression and other mental disorders account for about 40% of total global health expenditure on mental health and substance use disorder services (WHO financing context)
03
In the U.S., people with serious mental illness incur higher healthcare expenditures—roughly 2–3x those without serious mental illness (AHRQ/medical expenditure summaries)
04
A RAND evaluation found mental health treatment yields cost savings/benefits; psychotherapy benefits can outweigh costs in many scenarios (reported as positive benefit-cost ratios)
05
In a U.S. cost-effectiveness model, stepwise collaborative care for depression produced net savings with a probability of cost-effectiveness above 70% at common willingness-to-pay thresholds
06
Meta-analysis of economic evaluations reported that effective psychological therapies can reduce healthcare costs by measurable margins (average cost offsets reported in systematic reviews)
07
In the UK, a NICE health technology evaluation reported that CBT for depression can be cost-effective at typical cost-per-QALY thresholds (cost per QALY values reported)
08
NICE evaluations often use £20,000–£30,000 per QALY as a threshold range; CBT interventions frequently fall below this in published analyses (HTA evidence)
09
For PTSD, a U.S. economic analysis estimated that trauma-focused psychotherapy yields reductions in downstream costs for healthcare and disability (modeled cost impacts reported as dollars)
10
For insomnia, CBT-I can reduce productivity losses; studies estimate meaningful reductions in work impairment measured in days or hours (reported in economic evaluation)
11
In a large UK employer-based study, treating common mental health problems can reduce sickness absence by measurable percentages (reported reductions in days absent)
12
The WHO estimates that depression and anxiety cost the global economy about $1 trillion per year in lost productivity (WHO)
13
WHO estimates that mental health conditions result in disability-adjusted life years (DALYs) loss of millions globally for depression and anxiety combined (GBD-based summarized totals)
14
In the GBD, depressive disorders account for 50+ million DALYs annually globally (GBD results tool output depends on year/region selection)
15
In the GBD, anxiety disorders account for 40+ million DALYs annually globally (GBD results tool output depends on year/region selection)
16
Therapy can reduce functional impairment; in depression studies, functioning improvement is often captured as moderate effect sizes (standardized effects ~0.4+) in systematic reviews
17
For bipolar disorder, psychosocial interventions including CBT reduce relapse rates by measurable relative reductions reported in meta-analyses
18
In health system analyses, psychological therapy programs can reduce emergency department utilization for comorbid mental health presentations (modeled reductions reported)
19
In suicide prevention strategies, effective mental health interventions can reduce suicide mortality; guideline evidence often reports reductions in suicide attempts by clinically meaningful percentages (systematic review)
20
For self-harm and borderline symptoms, DBT reduces self-harm frequency; trial-level findings often report 1-year self-harm reduction by about 40% relative to controls in published RCTs
21
For children and adolescents, evidence-based therapies reduce school impairment; RCTs report improved attendance/functional outcomes measured as standardized improvements (effect sizes moderate)
22
In an RCT economic evaluation for depression collaborative care, incremental cost-effectiveness ratios (ICERs) were reported as within commonly accepted cost-effectiveness ranges (cost per QALY values reported)
23
In a systematic review, psychological interventions for depression reduced absenteeism and improved work functioning with measurable improvements captured by standardized outcomes
24
For anxiety disorders, CBT reduces healthcare utilization; meta-analyses report lower medical visits/utilization in intervention groups (reported as utilization reductions)
25
For OCD, family and CBT interventions reduce relapse risk; relapse rate reductions are reported as measurable percentages in trials
26
For PTSD, reductions in symptom severity correspond to reduced disability; studies report decreased Sheehan Disability Scale scores by clinically meaningful amounts
27
A randomized trial of CBT for depression reported improved productivity with changes in Work and Social Adjustment Scale (WSAS) scores by several points
Interpretation
Societal Impact Interpretation
Across conditions, psychotherapy looks increasingly like a high value investment because cost estimates show mental health burdens of $200+ billion in the US and about $1 trillion in lost global productivity, while multiple economic and trial findings report outcomes such as CBT for depression fitting common NICE cost per QALY thresholds and DBT reducing self harm frequency by about 40% over one year.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Catherine Wu. (2026, February 13). Psychotherapy Effectiveness Statistics. Gitnux. https://gitnux.org/psychotherapy-effectiveness-statistics
MLA
Catherine Wu. "Psychotherapy Effectiveness Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/psychotherapy-effectiveness-statistics.
Chicago
Catherine Wu. 2026. "Psychotherapy Effectiveness Statistics." Gitnux. https://gitnux.org/psychotherapy-effectiveness-statistics.
Sources & references
78 datasets cited across this report · attribution is report-level
+58 additional datasets cited (not shown individually)